SMIMB1151U Clinical Pharmacology and Biostatistics
Please note that this is the course description for the study year 2015/16. Information on course dates, prices etc. in coming semesters please visit www.mind.ku.dk
Master's Programme in Industrial Drug Development -
compulsory
Compulsory for Master of Industrial Drug Development (MIND)
students, elective for other part-time master's students at the
Faculty of Health and Medical Sciences (subject to study board
approval). Open for freelance students who meet the admission
criteria.
The course is intended for MIND students and other professionals in
drug development and health care.
The course covers the transition process of drug candidates from the preclinical stage to clinical evaluation comprising selection of special patient populations, PK/PD methodology, clinical trial designs, and regulatory aspects. Special emphasis will be put on biostatistics including theory, considerations and hands-on calculations for practical use. Further an introduction will be given to in silico trial simulation.
The objective of this course is to give participants a thorough
understanding of clinical pharmacological considerations during
drug development. This will prepare the participants to take active
part in the planning and execution of a clinical trial.
Upon completion of the course, participants are expected to be able
to:
Knowledge
- outline comprehensively the clinical pharmacological considerations made during drug development
- outline comprehensively the transition process from preclinical to man
- outline basic biostatistical concepts for a clinical trial
- describe the regulatory requirements for a clinical trial
- demonstrate knowledge of basic clinical pharmacology as prerequisites for planning a clinical trial
- demonstrate knowledge of pharmacometrics to optimise trial design
Skills
- write a protocol on a clinical trial to be valid for the clinic
- calculate statistics and the power of a clinical study
Competencies
- plan and critically evaluate a clinical trial
- handle translational information from the preclinical to the clinical setting
- identify a special patient population for the trial
- liaise and communicate professionally using clinical pharmacology and clinical trial terminology
Chapter 6-9 in Pharmaceutical Medicines ed. J.P Griffin 6th ed. 2010 (100 pages), scientific articles of relevance (16 pages), guidelines (17 pages), notes on biostatistic (15 pages), hand-outs of presentations from lectures ( approximately 135 pages). Total 310 pages.
• A relevant bachelor degree or equivalent
• A minimum of 2 years of relevant job experience
• Proficiency in English
- Category
- Hours
- Exam
- 1
- Lectures
- 30
- Preparation
- 59
- Project work
- 30
- Theory exercises
- 20
- Total
- 140
- Credit
- 5 ECTS
- Type of assessment
- Written assignmentWritten examination, 1 hour under invigilationExamination design:
1. The written trial protocol. The protocol is written during course to be delivered Thursday the last week. The assessment of the protocol comprises the mode of handling of the posed problem, its solution and the demonstrated level of critical understanding of clinical pharmacology in drug development and the individual presentation. The written trial protocol can be written in groups.
2. Essay and multiple choice exam (1 hour) under invigilation. Each student answers a written exam consisting of short problems and multiple choice questions.
1) and 2) covers 50 % of the final mark, respectively. - Aid
- All aids allowed
Apart from the standard programs and IT tools listed under The Faculty of Health and Medical Sciences at http://pc-exam.ku.dk/it_tools/health/ students will at this exam also have access to use a USB stick (for notes etc.)
Certain pocket calculators are allowed.
- Marking scale
- 7-point grading scale
- Censorship form
- External censorship
- Exam period
13 November 2015. 3-4 pm.
- Re-exam
14 December 2015.
Criteria for exam assesment
The purpose of the examination is to test that the examinee has a broad knowledge and comprehension of clinical pharmacology in drug development. To pass the examination the student must be able to:
- evaluate proof of concept of efficacy and safety in the clinical setting
- apply biomarkers as surrogate endpoints
- describe conditions for performing first-in-man studies
- select groups at risk for at trial
- establish the correlation between pharmacokinetics and pharmacodynamics of a drug
- write a simple protocol for a clinical trial according to current regulatory guidelines and GCP
- calculate basic statistics relevant for measures of clinical effects of drug treatment
The grade 12 is given for an excellent performance displaying a
high level of command of all aspects of the relevant material, with
no or only a few minor weaknesses.
The grade 7 is given for a good performance displaying good command of the relevant material but also some weaknesses.
The grade 02 is given for a performance meeting only the minimum requirements for acceptance.
Course information
- Language
- English
- Course code
- SMIMB1151U
- Credit
- 5 ECTS
- Level
- Part Time Master
- Duration
- 26-30 October and 9-13 November 2015.
- Placement
- Autumn
- Schedule
- .
- Course capacity
- 24 participants
- Continuing and further education
- Price
Part-time master’s students at Faculty of Health and Medical Sciences DKK 18,080, freelance students DKK 21,000, freelance students from non-EU/EEA countries DKK 24,800. Fee includes course materials and meals. Prices may be subject to change.
- Study board
- Study Board for Part-time Master’s Programmes of Pharmaceutical Sciences
Contracting department
- Department of Drug Design and Pharmacology
Course responsibles
- Ole Jannik Bjerrum (ojb@sund.ku.dk)
Professor Emeritus
Lecturers
List of lecturers may be subject to change.
Alejandra Mørk, Klifo
Anders Grahnén, Uppsala University
Christian Gluud, CTU, Rigshospitalet – Copenhagen University
Hospital
Connie Brendstrup, Roche
Ewa Lindenstrøm, EL Medical Consulting
Frank Larsen, Lundbeck
Helle Northeved, Lundbeck
Helmer Ring-Larsen, University of Copenhagen
Henrik Tang Vestergaard, Danish Medicines Agency
Jane Arce, Nordic Trial Operations
Jens Peter Balling, Lundbeck
Judith Jacobsen, Statcon ApS, Biostatistic Department, University
of Copenhagen
Mette Damholt, Rigshospitalet - Copenhagen University Hospital
Morten Mau-Sørensen, Finsen Institute
Ove Andersen, Hvidovre Hospital
Steen Ingwersen, Novo Nordisk